Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

(2012) Douglas G Altman et al.   BMC Medicine

Topoisomerase 1(TOP1 ) gene copy number in stage III colorectal cancer patients and its relation to prognosis

(2012) Maria Unni Rømer et al.   Molecular Oncology

The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures

(2011) Yueyao Du et al.   BREAST CANCER RESEARCH AND TREATMENT

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

(2011) Angelo Di Leo et al.   LANCET ONCOLOGY

Implications of rarity of chromosome 17 polysomy in breast cancer

(2011) Cathy B Moelans et al.   LANCET ONCOLOGY

Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status

(2011) Kirsten Vang Nielsen et al.   Molecular Oncology

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Be precise! The need to consider the mechanisms forCEP17copy number changes in breast cancer

(2009) Giuseppe Viale   JOURNAL OF PATHOLOGY

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis

(2009) Caterina Marchiò et al.   JOURNAL OF PATHOLOGY

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

(2009) Monica M Reinholz et al.   LANCET ONCOLOGY